Trimethoprim and sulfamethoxazole were tested alone and in combination against 227 recently isolated Shigella strains. Variations in medium constituents and inoculum size were used to determine the optimal testing conditions. The plate dilution method with addition of 5% lysed horse blood to the susceptibility test medium and an inoculum size of 102 organisms was found to provide satisfactory results. All 227 strains were inhibited by low concentrations of trimethoprim, and all were susceptible to the combination of 0.06 ug of trimethoprim per ml and 1.25 ,ug of sulfamethoxazole per ml. Sixteen percent of these strains were resistant to ampicillin, 33% to tetracycline, 15% to chloramphenicol, and 27% to cephalothin. Based on these in vitro observations, trimethoprim and sulfamethoxazole appear worth evaluating for treatment of shigellosis due to multiply antibiotic-resistant strains.
ance in 50% of strains in Tennessee. A recent communication from our laboratory (6) showed that the same ttend to ampicillin resistance is also occurring in Dallas. Until 1971, only 4% of Shigella strains in Dallas were resistant to ampicillin, but in 1972, 14% of S. flexneri and 25% of S. sonnei were found to be resistant to ampicillin. Ampicillin-resistant strains are usually resistant to multiple antibiotics. This precipitous emergence of Shigella resistance to multiple antimicrobial agents indicates the need for new agents able to cope with this increasing problem.
Trimethoprim (TMP) and sulfamethoxazole (SMX) were inhibitory in vitro to all 209 S. sonnei strains isolated in England (10) . Ninetytwo percent were resistant to ampicillin. In a study from Thailand, 104 Shigella strains were susceptible to TMP-SMX (11) . Only 9% of those strains were resistant to ampicillin, but 84% were tetracycline resistant and 88.5% chloramphenicol resistant. In a comparative study with Franzen et al. (5) in Sweden during a clinical trial using TMP-SMX and a placebo. All strains were inhibited by TMP, but 28% were resistant to ampicillin and 86% to sulfonamides. They noted reduction of the excretion period in all patients receiving TMP-SMX, but were not able to assess the effect on symptoms because almost all patients studied were asymptomatic excretors.
No data were available on TMP-SMX efficacy against Shigella strains isolated in the United States, but the cited reports from England, Thailand, and Sweden were encouraging that this drug combination might prove useful for treatment of shigellosis. Therefore, preparatory to beginning clinical trials, we performed the following in vitro studies with 227 Shigella strains of varying antibiotic susceptibility patterns which were isolated in Dallas. 
MATERIALS AND METHODS

RESULTS
Inoculum size and the addition of 5% lysed horse blood to the media influenced markedly the MICs (Tables -1, All the 227 Shigella strains tested with TMP and SMX were inhibited by TMP at concentrations of 0.08 ,ug/ml or less (Fig. 1) . In general, S.
sonnei strains had MICs one to two concentrations higher than S. flexneri strains. Fifty percent of the S. flexneri strains and 38% of the S. sonnei strains were susceptible to an SMX level of 80 4g/ml (Fig. 2) . Two distinct populations were observed: one very susceptible to SMX with MICs of 1.25 gg/ml or less and the other showing marked resistance. Very few strains occupied the area between these two groups. The addition of SMX slightly modified the MICs of TMP, perhaps indicating a synergistic effect of the combination (Fig. 3) . With the Table 4 . No major differences were noted between S. sonnei and S. flexneri strains in the multiple-resistance pattern: 43.7% of the S. sonnei and 53.5% of S. flexneri were susceptible to the four antibiotics, and 3% of the total strains were resistant to all four drugs tested.
DISCUSSION
The influence of the medium constituents and inoculum size on apparent inhibitory concentrations of TMP and SMX is a well-known fact (15) . The inoculum should be small and the medium free of end products of folate metabolism that may erroneously produce a pattern of resistance by enabling the organism to by-pass the double blockade of folate synthesis induced by TMP and SMX (3) . Under the testing conditions of this study, a medium with low content of peptone, such as sensitivity test agar, with the addition of lysed horse blood was found to produce conditions nearly optimal for the testing of these antimicrobial agents. The effect of equine blood lysate was first described by Harper and Cawston (9) , confirmed by Walker et al. (14) , and recently identified by Bushby (2) as being due to thymidine phosphorylase, an enzyme that converts thymidine to thymine, which has less inhibitory action against TMP and SMX than thymidine.
Although the 15.6% frequency of ampicillin resistance is lower than that reported from other areas, it reflects a definite increase over our experience prior to 1972 (6) . All strains were very susceptible to TMP alone or to the combination of TMP-SMX at concentrations easily exceeded in blood with usual therapeutic dosages (14) . The addition of SMX slightly reduced the TMP MIC, especially of S. flexneri strains susceptible to sulfa, but this was not a striking potentiation. Jarvis and Scrimgeour noted potentiation of inhibition against SMX-susceptible S. sonnei but not against SMX-resistant strains (10) . Sulfa (11) and Sweden (5) suggest that TMP alone or the combination of TMP-SMX may be useful for treatment of shigellosis. Well-controlled clinical trials are needed to establish this.
